Tactile Systems Technology, Inc. (NASDAQ:TCMD) Director Sells $159,147.90 in Stock

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Director Daniel L. Reuvers sold 10,938 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $14.55, for a total transaction of $159,147.90. Following the sale, the director now directly owns 242,942 shares in the company, valued at $3,534,806.10. This trade represents a 4.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Tactile Systems Technology Stock Down 1.0 %

TCMD traded down $0.15 during mid-day trading on Monday, reaching $14.90. 483,839 shares of the stock were exchanged, compared to its average volume of 299,195. Tactile Systems Technology, Inc. has a 1 year low of $11.12 and a 1 year high of $21.10. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.80 and a current ratio of 4.36. The stock has a market capitalization of $351.42 million, a PE ratio of 21.29 and a beta of 1.20. The company has a 50 day moving average price of $17.26 and a two-hundred day moving average price of $15.71.

Tactile Systems Technology (NASDAQ:TCMD) last issued its quarterly earnings results on Tuesday, February 18th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.09. The business had revenue of $85.59 million for the quarter, compared to analyst estimates of $85.39 million. Tactile Systems Technology had a return on equity of 9.37% and a net margin of 5.79%. As a group, research analysts anticipate that Tactile Systems Technology, Inc. will post 0.7 EPS for the current year.

Institutional Trading of Tactile Systems Technology

Large investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp grew its position in shares of Tactile Systems Technology by 164.1% during the 4th quarter. Mackenzie Financial Corp now owns 36,295 shares of the company’s stock valued at $622,000 after acquiring an additional 22,551 shares during the period. PharVision Advisers LLC bought a new stake in shares of Tactile Systems Technology in the 4th quarter worth approximately $306,000. Virtus Fund Advisers LLC lifted its stake in Tactile Systems Technology by 142.0% in the fourth quarter. Virtus Fund Advisers LLC now owns 4,199 shares of the company’s stock valued at $72,000 after purchasing an additional 2,464 shares during the last quarter. Virtus Investment Advisers Inc. grew its holdings in Tactile Systems Technology by 74.6% during the fourth quarter. Virtus Investment Advisers Inc. now owns 27,931 shares of the company’s stock valued at $478,000 after purchasing an additional 11,930 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Tactile Systems Technology in the fourth quarter worth $239,000. Hedge funds and other institutional investors own 83.43% of the company’s stock.

Analyst Upgrades and Downgrades

TCMD has been the topic of a number of recent analyst reports. Oppenheimer downgraded Tactile Systems Technology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. B. Riley lowered Tactile Systems Technology from a “buy” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $18.00 in a research note on Wednesday, February 19th. StockNews.com cut Tactile Systems Technology from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 16th. Finally, BTIG Research lowered shares of Tactile Systems Technology from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 5th.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.